As filed with the Securities and Exchange Commission on March 29, 2018
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FormS-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Ovid Therapeutics Inc.
(Exact name of registrant as specified in its charter)
Delaware | 46-5270895 | |
(State or other jurisdiction of incorporation or organization) | (IRS employer identification number) |
1460 Broadway, Suite 15044 New York, New York | 10036 | |
(Address of Principal Executive Offices) | (Zip Code) |
2017 Equity Incentive Plan
2017 Employee Stock Purchase Plan
(Full titles of the plans)
Jeremy M. Levin, DPhil, MB BChir
Chief Executive Officer
Ovid Therapeutics Inc.
1460 Broadway, Suite 15044
New York, New York 10036
(646)661-7661
(Name, address, including zip code and telephone number, including area code, of agent for service)
Copies to:
Ana C. Ward Senior Vice President and General Counsel Ovid Therapeutics Inc. 1460 Broadway, Suite 15044 New York, New York 10036 (646)661-7661 | Laura A. Berezin Jaime L. Chase Cooley LLP 3175 Hanover Street Palo Alto, California 94304 (650)843-5000 |
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, anon-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer | (Do not check if a smaller reporting company) ☒ | Smaller reporting company | ☐ | |||
Emerging growth company | ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒
CALCULATION OF REGISTRATION FEE
| ||||||||
Title of Securities To Be Registered | Amount To Be | Proposed Maximum Offering Price Per Share | Proposed Offering Price | Amount of Registration Fee | ||||
2017 Equity Incentive Plan (Common stock, $0.001 par value per share) | 1,230,312(2) | $7.525(4) | $9,258,097.80(4) | $1,073.01 | ||||
2017 Employee Stock Purchase Plan (Common stock, $0.001 par value per share) | 246,062(3) | $7.525(4) | $1,851,616.55(5) | $214.60 | ||||
TOTAL | 1,476,374 | $11,109,714.35 | $1,383.16 | |||||
| ||||||||
|
(1) | Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of common stock that become issuable under the above-named plans by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without receipt of consideration which results in an increase in the number of Ovid Therapeutics Inc.’s (the “Registrant”) outstanding shares of common stock, par value $0.001 per share (the “Common Stock”). |
(2) | Represents additional shares of the Registrant’s Common Stock reserved for future grant under the Ovid Therapeutics Inc. 2017 Equity Incentive Plan (the “2017 Plan”) as a result of the automatic increase in shares reserved thereunder on January 1, 2018 pursuant to the terms of the 2017 Plan. The 2017 Plan provides that an additional number of shares will automatically be added annually to the shares authorized for issuance under the 2017 on January 1, from 2018 until the expiration of the 2017 Plan in an amount equal to the lesser of (a) 5% of the total number of shares of capital stock outstanding on December 31st of the preceding calendar year and (b) a number of shares of Common Stock designated by action of the Registrant’s board of directors prior to the first day of any calendar year. |
(3) | Represents additional shares of the Registrant’s Common Stock reserved for issuance under the Ovid Therapeutics Inc. 2017 Employee Stock Purchase Plan (the “ESPP”) as a result of the automatic increase in shares reserved thereunder on January 1, 2018 pursuant to the terms of the ESPP. The ESPP provides that an additional number of shares will automatically be added annually to the shares authorized for issuance under the ESPP on January 1, from 2018 until January 1, 2027. The number of shares added each year will be equal to the lesser of: (a) 1% of the total number of shares of the Registrant’s capital stock outstanding on December 31 of the preceding calendar year; (b) 550,000 shares of Common Stock and (c) a number of shares of Common Stock designated by action of the Registrant’s board of directors prior to the first day of any calendar year. |
(4) | Estimated pursuant to Rule 457(c) and Rule 457(h) solely for the purpose of calculating the registration fee. The proposed maximum offering price per share and proposed maximum aggregate offering price are based on the average of the high and low sale prices of the Common Stock as reported on The Nasdaq Global Select Market on March 26, 2018. |
PART I
EXPLANATORY NOTE
The Registrant is filing this Registration Statement on FormS-8 for the purpose of registering an additional 1,230,312 shares of common stock under the Ovid Therapeutics Inc. 2017 Equity Incentive Plan and an additional 246,062 shares of common stock under the Ovid Therapeutics Inc. Employee Stock Purchase Plan, pursuant to the provisions of each plan which provide for annual automatic increases in the number of shares of common stock reserved for issuance under each respective plan.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. | Incorporation of Documents by Reference. |
Ovid Therapeutics Inc. (the “Registrant”) hereby incorporates by reference into this Registration Statement the following documents filed by it with the Commission:
(a) | the contents of the Registrant’s Registration Statement on FormS-8, previously filed with the Commission on May 22, 2017 (FileNo. 333-218167); |
(b) | the Registrant’s Annual Report on Form10-K (FileNo. 001-38085) for the year ended December 31, 2017, filed with the Commission on March 29, 2018; |
(c) | the Registrant’s Current Report on Form8-K (FileNo. 001-38085) filed with the Commission on January 24, 2018; and |
(d) | The description of the Common Stock contained in the Registrant’s Registration Statement on Form8-A (FileNo. 001-38085) filed with the Commission on May 4, 2017, under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendments or reports filed for the purpose of updating such description. |
All documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such documents, except as to specific sections of such documents as set forth therein. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein or in any subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not constitute a part of this Registration Statement, except as so modified or superseded.
Item 8. | Exhibits. |
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on FormS-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York on March 29, 2018.
Ovid Therapeutics Inc. | ||
By: | /s/ Jeremy M. Levin, DPhil, MB BChir | |
Jeremy M. Levin, DPhil, MB BChir | ||
Chief Executive Officer |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jeremy M. Levin, DPhil, MB BChir and Timothy Daly, and each or any one of them, his or her true and lawfulattorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto saidattorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that saidattorneys-in-fact and agents, or any of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on FormS-8 has been signed by the following persons in the capacities and on the dates indicated.
Signature | Title | Date | ||
/s/ Jeremy M. Levin, DPhil, MB BChir Jeremy M. Levin, DPhil, MB BChir | Chief Executive Officer and Director (Principal Executive Officer) | March 29, 2018 | ||
/s/ Timothy Daly Timothy Daly | Senior Vice President, Finance and Corporate Controller (Principal Financial and Accounting Officer) | March 29, 2018 | ||
/s/ Matthew During, MD, DSc Matthew During, MD, DSc | President, Chief Scientific Officer and Director | March 29, 2018 | ||
/s/ Karen Bernstein, PhD Karen Bernstein | Director | March 29, 2018 | ||
/s/ Barbara Duncan Barbara Duncan | Director | March 29, 2018 | ||
/s/ Bart Friedman Bart Friedman | Director | March 29, 2018 | ||
/s/ Douglas Williams, PhD Douglas Williams, PhD | Director | March 29, 2018 |